Ligands for kainate subtype glutamate receptors

Expert Opinion on Therapeutic Patents

Volumn 14, Issue 4, 2004, Pages 471-486

  Shou, Xiaohong ^a   Chamberlin, A Richard ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Agonist; AMPA; Antagonist; Decahydroxyisoquinoline; Glutamate; Kainate; Kainic acid; Kainoid; Modulator; Neuronal disease; Quinoxalinedione; Receptor; Willardiine

Indexed keywords

2 AMINO 3 (3 HYDROXY 7,8 DIHYDRO 6H CYCLOHEPTA[D]ISOXAZOL 4 YL)PROPIONIC ACID; 2 AMINO 3 (5 TERT BUTYL 3 HYDROXYISOTHIAZOL 4 YL)PROPIONIC ACID; 2,3 DIHYDRO 6 NITRO 7 SULFAMOYLBENZOQUINOXALINE; 3 (4 CARBOXYBENZYL)WILLARDIINE; 4 (2 THIAZOLYLMETHYLENE)GLUTAMIC ACID; 4 (2,2 DIMETHYLPROPYLIDENE)GLUTAMIC ACID; 4 [3 (2 NAPHTHYL)ALLYL]GLUTAMIC ACID; 4 METHYLGLUTAMIC ACID; 5 IODOWILLARDIINE; 5 TRIFLUOROMETHYLWILLARDIINE; 6 CYANO 7 NITRO 2,3 QUINOXALINEDIONE; AMPA RECEPTOR; AMPA RECEPTOR AGONIST; AMPA RECEPTOR ANTAGONIST; BSF 84077; BSF 91594; CATION CHANNEL; DOMOIC ACID; GLUTAMATE RECEPTOR; GLUTAMATE RECEPTOR AGONIST; GLUTAMATE RECEPTOR ANTAGONIST; GLUTAMIC ACID DERIVATIVE; KAINIC ACID RECEPTOR; KAINIC ACID RECEPTOR AGONIST; KAINIC ACID RECEPTOR ANTAGONIST; LY 339624; NEW DRUG; QUINOXALINE DERIVATIVE; RECEPTOR SUBTYPE; THIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

BINDING AFFINITY; CANCER THERAPY; DRUG DESIGN; DRUG DETERMINATION; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG SELECTIVITY; DRUG STRUCTURE; HUMAN; IN VITRO STUDY; LIGAND BINDING; MOUSE; NEUROLOGIC DISEASE; NEUROPATHIC PAIN; NONHUMAN; OBESITY; PATENT; PROTEIN FAMILY; RECEPTOR BLOCKING; REVIEW; SIDE EFFECT; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

EID: 1942504301     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.14.4.471     Document Type: Review

References (115)

1. SHERIDAN PH, WEIGHT FF, HERMAN BH: Molecular Pharmacology and Physiology of Glutamate Receptors. In: Glutamate and Addiction. Herman B (Ed.) Humana Press, Totowa, USA (2003):3-71.
2. BIGGE CF: Ionotropic glutamate receptors. Curr. Opin. Chem. Biol. (1999) 3:441-447.
3. KOLES L, WIRKNER K, ILLES P: Modulation of ionotropic glutamate receptor channels. Neurochem. Res. (2001) 26:925-932.
4. FAROOQUI AA, HORROCKS LA: Excitatory amino acid receptors, neural membrane phospholipid metabolism and neurological disorders. Brain Res. Brain Res. Rev. (1991) 16:171-191.
5. CHOI DW: Glutamate neurotoxicity and diseases of the nervous system. Neuron (1988) 1:623-634.
6. LODGE D: Subtypes of glutamate receptors: Historical perspectives on their pharmacological differentiation. In: The ionotropic glutamate receptors. Wenthold RJ (Ed.) Humana Press, New Jersey, USA (1997):1-38.
7. HARRIS EW: Subtypes of Glutamate Receptors: Pharmalogical Classification. In: CNS neurotransmitters and neuromodulators glutamate. Stone TW (Ed.) CRC Press, New York, USA (1995):95-126.
8. STRICKER NL, HUGANIR R: AMPA/kainate receptors. In: Receptor and Ion-Channel Trafficking. Henley J (Ed.) Oxford University Press, New York, USA (2002):131-155.
9. MYERS SJ, DINGLEDINE R, BORGES K: Genetic regulation of glutamate receptor ion channels. Ann. Rev Pharmacol. Toxicol. (1999) 39:221-241.
10. WATKINS JC, KROGSGAARD-LARSEN P, HONORE T: Structure-activity relationships in the development of excitatory amino acid receptor agonists and competitive antagonists. Trends Pharmacol. Sci. (1990) 11:25-33.
11. DINGLEDINE R, BORGES K, BOWIE D, TRAYNELIS SF: The glutamate receptor ion channels. Pharmacol. Rev. (1999) 51:7-61.
12. ROSENMUND C, STERN-BACH Y, STEVENS CF: The tetrameric structure of a glutamate receptor channel. Science (1998) 280:1596-1599.
13. LEUSCHNER WD, HOCH W: Subtype-specific assembly of α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor subunits is mediated by their N-terminal domains. J. Biol. Chem. (1999) 274:16907-16916.
14. STERN-BACH Y, BETTLER B, HARTLEY M et al.: Agonist selectivity of glutamate receptors is specified by two domains structurally related to bacterial amino acid-binding proteins. Neuron (1994) 13:1345-1357.
15. KEINANEN K, ARVOLA M, KUUSINEN A, JOHNSON M: Ligand recognition in glutamate receptors: insights from mutagenesis of the soluble alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA)-binding domain of glutamate receptor type D (GluR-D). Biochem. Soc. Trans. (1997) 25:835-838.
16. KUUSINEN A, ARVOLA M, KEINANEN K: Molecular dissection of the agonist binding site of an AMPA receptor. Embo. J. (1995) 14:6327-6332.
17. KEINANEN K, JOUPPILA A, KUUSINEN A: Characterization of the kainate-binding domain of the glutamate receptor GluR-6 subunit. Biochem. J. (1998) 330(Pt3):1461-1467.
18. ARMSTRONG N, SUN Y, CHEN GQ, GOUAUX E: Structure of a glutamate-receptor ligand-binding core in complex with kainate. Nature (1998) 395:913-917.
19. SUN Y, OLSON R, HORNING M et al.: Mechanism of glutamate receptor desensitization. Nature (2002) 417:245-253.
20. ARMSTRONG N, GOUAUX E: Mechanisms for activation and antagonism of an AMPA-sensitive glutamate receptor: Crystal structures of the GluR2 ligand binding core. Neuron (2000) 28:165-181.
21. FURUKAWA H, GOUAUX E: Mechanisms of activation, inhibition and specificity: crystal structures of the NMDA receptor NR1 ligand-binding core. Embo. J. (2003) 22:2873-2885.
22. HOGNER A, KASTRUP JS, JIN R et al.: Structural basis for AMPA receptor activation and ligand selectivity: crystal structures of five agonist complexes with the GluR2 ligand-binding core. J. Mol. Biol. (2002) 322:93-109.
23. HOGNER A, GREENWOOD JR, LILJEFORS T et al.: Competitive antagonism of AMPA receptors by ligands of different classes: crystal structure of ATPO bound to the GluR2 ligand-binding core, in comparison with DNQX. J. Med. Chem. (2003) 46:214-221.
24. JIN R, HORNING M, MAYER ML, GOUAUX E; Mechanism of activation and selectivity in a ligand-gated ion channel: structural and functional studies of GluR2 and quisqualate. Biochemistry (2002) 41:15635-15643.
25. JIN R, BANKE TG, MAYER ML, TRAYNELIS SF, GOUAUX E: Structural basis for partial agonist action at ionotropic glutamate receptors. Nat. Neurosci. (2003) 6:803-810.
26. KASPER C, LUNN ML, LILJEFORS T et al.: GluR2 ligand-binding core complexes: importance of the isoxazolol moiety and 5-substituent for the binding mode of AMPA-type agonists. FEBS Lett. (2002) 531:173-178.
27. HOLLMANN M, HEINEMANN S: Cloned glutamate receptors. Ann. Rev. Neurosci. (1994) 17:31-108.
28. WERNER P, VOIGT M, KEINANEN K, WISDEN W, SEEBURG PH: Cloning of a putative high-affinity kainate receptor expressed predominantly in hippocampal CA3 cells. Nature (1991) 351:742-744.
29. HERB A, BURNASHEV N, WERNER P et al.: The KA-2 subunit of excitatory amino acid receptors shows widespread expression in brain and forms ion channels with distantly related subunits. Neuron (1992) 8:775-785.
30. KAMBOJ RK, SCHOEPP DD, NUTT S et al.: Molecular cloning, expression, and pharmacological characterization of humEAA1, a human kainate receptor subunit. J. Neurochem. (1994) 62:1-9.
31. PATERNAIN AV, HERRERA MT, NIETO MA, LERMA J: GluR5 and GluR6 kainate receptor subunits coexist in hippocampal neurons and coassemble to form functional receptors. J. Neurosci. (2000) 20:196-205.
32. CUI C, MAYER ML: Heteromeric kainate receptors formed by the coassembly of GluR5, GluR6, and GluR7. J. Neurosci. (1999) 19:8281-8291.
33. BLEAKMAN D, LODGE D: Neuropharmacology of AMPA and kainate receptors. Neuropharmacology (1998) 37:1187-1204.
34. CHITTAJALLU R, BRAITHWAITE SP, CLARKE VR, HENLEY JM: Kainate receptors: subunits, synaptic localization and function. Trends Pharmacol. Sci. (1999) 20:26-35.
35. BETTLER B, BOULTER J, HERMANS-BORGMEYER I et al.: Cloning of a novel glutamate receptor subunit, GluR5: expression in the nervous system during development. Neuron (1990) 5:583-595.
36. RUSCHEWEYH R, SANDKUHLER J: Role of kainate receptors in nociception. Brain Res. Brain Res. Rev. (2002) 40:215-222.
37. LERMA J, PATERNAIN AV, RODRIGUEZ-MORENO A, LOPEZ-GARCIA JC: Molecular physiology of kainate receptors. Physiol. Rev. (2001) 81:971-998.
38. CLARKE VR, BALLYK BA, HOO KH et al.: A hippocampal GluR5 kainate receptor regulating inhibitory synaptic transmission. Nature (1997) 389:599-603.
39. RODRIGUEZ-MORENO A. HERRERAS O, LERMA J: Kainate receptors presynaptically downregulate GABAergic inhibition in the rat hippocampus. Neuron (1997) 19:893-901.
40. RODRIGUEZ-MORENO A, LERMA J: Kainate receptor modulation of GABA release involves a metabotropic function. Neuron (1998) 20:1211-1218.
41. CASTILLO PE, MALENKA RC, NICOLL RA: Kainate receptors mediate a slow postsynaptic current in hippocampal CA3 neurons. Nature (1997) 388:182-186.
42. VIGNES M, BLEAKMAN D, LODGE D, COLLINGRIDGE GL: The synaptic activation of the GluR5 subtype of kainate receptor in area CA3 of the rat hippocampus. Neuropharmacology (1997) 36:1477-1481.
43. VIGNES M, COLLINGRIDGE GL: The synaptic activation of kainate receptors. Nature (1997) 388:179-182.
44. LERMA J: Roles and rules of kainate receptors in synaptic transmission. Nat Rev. Neurosci. (2003) 4:481-495.
45. MURAKAMI S, TAKEMOTO T, SHIMIZU Z: The effective principle of Digenea simplex Aq. I. Separation of the effective fraction by liquid chromatography. Yakugaku Zasshi (1953) 73:1026-1028.
46. YOUNG AB, FAGG GE: Excitatory amino acid receptors in the brain: membrane binding and receptor autoradiographic approaches. Trends Pharmacol. Sci. (1990) 11:126-133.
47. BRAUNER-OSBORNE H, EGEBJERG J, NIELSEN EO, MADSEN U, KROGSGAARD-LARSEN P: Ligands for glutamate receptors: design and therapeutic prospects. J. Med. Chem. (2000) 43:2609-2645.
48. SONNENBERG JD, KOCH HP, WILLIS CL et al.: The role of the C-4 side chain of kainate and dihydrokainate in EAA receptor and transporter selectivity. Bioorg. Med. Chem. Lett. (1996) 6:1607-1612.
49. BALDWIN JE, FRYER AM, PRITCHARD GJ: Parallel synthesis of novel heteroaromatic acromelic acid analogues from kainic acid. J. Org. Chem. (2001) 66:2588-2596.
50. HUETTNER JE: Functional Properties of Kainate Receptors. In: The Ionotropic Glutamate Receptors. Wenthold RJ (Ed.) Humana Press, New Jersey, USA (1997):265-284.
51. WONG LA, MAYER ML, JANE DE, WATKINS JC: Willardiines differentiate agonist binding sites for kainate- versus AMPA-preferring glutamate receptors in DRG and hippocampal neurons. J. Neurosci. (1994) 14:3881-3897.
52. 3H]-5-fluorowillardiine binding in rat brain. Br. J. Pharmacol. (1995) 116:2033-2039.
53. VERDOORN TA, JOHANSEN TH, DREJER J, NIELSEN EO: Selective block of recombinant glur6 receptors by NS-102, a novel non-NMDA receptor antagonist. Eur. J. Pharmacol. (1994) 269:43-49.
54. SCHMITZ D, MELLOR J, FRERKING M, NICOLL RA: Presynaptic kainate receptors at hippocampal mossy fiber synapses. Proc. Natl. Acad. Sci. USA (2001) 98:11003-11008.
55. SMALL B, THOMAS J, KEMP M et al.: LY339434, a GluR5 kainate receptor agonist. Neuropharmacology (1998) 37:1261-1267.
56. MOLDRICH RX, CHEUNG NS, PASCOE CJ et al.: Excitotoxic profile of LY-339434, a GluR5 agonist, in cultured murine cortical neurons. Brain Res. (2000) 862:270-275.
57. DONEVAN SD, BEG A, GUNTHER JM, TWYMAN RE: The methylglutamate, SYM-2081, is a potent and highly selective agonist at kainate receptors. J. Pharmacol. Exp. Ther. (1998) 285:539-545.
58. BUNCH L, JOHANSEN TH, BRAUNER-OSBORNE H et al.: Synthesis and receptor binding affinity of new selective GluR5 ligands. Bioorg. Med. Chem. (2001) 9:875-879.
59. VALGEIRSSON J, CHRISTENSEN JK, KRISTENSEN AS et al.: Synthesis and in vitro pharmacology at AMPA and kainate preferring glutamate receptors of 4-heteroarylmethylidene glutamate analogues. Bioorg. Med. Chem. (2003) 11:4341-4349.
60. STENSBOL TB, BORRE L, JOHANSEN TN et al.: Resolution, absolute stereochemistry and molecular pharmacology of the enantiomers of ATPA. Eur. J. Pharmacol. (1999) 380:153-162.
61. 3H]-ATPA: a high affinity ligand for GluR5 kainate receptors. Neuropharmacology (1999) 38:1811-1817.
62. BREHM L, GREENWOOD JR, HANSEN KB et al.: (S)-2-Amino-3-(3-hydroxy-7,8-dihydro-6H-cyclohepta[d]isoxazol-4-yl propionic acid, a potent and selective agonist at the GluR5 subtype of ionotropic glutamate receptors. Synthesis, modeling, and molecular pharmacology. J. Med. Chem. (2003) 46:1350-1358.
63. STENSBOL TB, JENSEN HS, NIELSEN B et al.: Stereochemistry and molecular pharmacology of (S)-thio-ATPA, a new potent and selective GluR5 agonist. Eur. J. Pharmacol. (2001) 411:245-253.
64. BLEAKMAN R, SCHOEPP DD, BALLYK B et al.: Pharmacological discrimination of GluR5 and GluR6 kainate receptor subtypes by (3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahyd roisdoquinoline-3 carboxylic-acid. Mol. Pharmacol. (1996) 49:581-585.
65. HAMPSON DR, MANALO JL: The activation of glutamate receptors by kainic acid and domoic acid. Nat. Toxins (1998) 6:153-158.
66. BAKER SR, BLEAKMAN D, EZQUERRA J et al.: 4-Alkylidenyl glutamic acids, potent and selective GluR5 agonists. Bioorg. Med. Chem. Lett. (2000) 10:1807-1810.
67. PEDREGAL C, COLLADO I, ESCRIBANO A et al.: 4-Alkyl- and 4-cinnamylglutamic acid analogues are potent GluR5 kainate receptor agonists. J. Med. Chem. (2000) 43:1958-1968.
68. BLEAKMAN D, OGDEN AM, ORNSTEIN PL, HOO K: Pharmacological characterization of a GluR6 kainate receptor in cultured hippocampal neurons. Eur. J. Pharmacol. (1999) 378:331-337.
69. JAKOBSEN B, TASKER A, ZIMMER J: Domoic acid neurotoxicity in hippocampal slice cultures. Amino Acids (2002) 23:37-44.
70. THOMAS NK, HAWKINS LM, MILLER JC et al.: Pharmacological differentiation of kainate receptors on neonatal rat spinal motoneurones and dorsal roots. Neuropharmacology (1998) 37:1223-1237.
71. JANE DE, HOO K, KAMBOJ R et al.: Synthesis of willardiine and 6-azawillardiine analogs: pharmacological characterization on cloned homomeric human AMPA and kainate receptor subtypes. J. Med. Chem. (1997) 40:3645-3650.
72. SWANSON GT, GREEN T, HEINEMANN SF: Kainate receptors exhibit differential sensitivities to (S)-5-iodowillardiine. Mol. Pharmacol. (1998) 53:942-949.
73. SOMMER B, BURNASHEV N, VERDOORN TA et al.: A glutamate receptor channel with high affinity for domoate and kainate. Embo. J. (1992) 11:1651-1656.
74. SCHIFFER HH, SWANSON GT, HEINEMANN SF: Rat GluR7 and a carboxy-terminal splice variant, GluR7b, are functional kainate receptor subunits with a low sensitivity to glutamate. Neuron (1997) 19:1141-1146.
75. LEES GJ: Pharmacology of AMPA/kainate receptor ligands and their therapeutic potential in neurological and psychiatric disorders. Drugs (2000) 59:33-78.
76. JONES KA, WILDING TJ, HUETTNER JE, COSTA AM: Desensitization of kainate receptors by kainate, glutamate and diastereomers of 4-methylglutamate. Neuropharmacology (1997) 36:853-863.
77. WAHL P, MADSEN U, BANKE T, KROGSGAARD-LARSEN P, SCHOUSBOE A: Different characteristics of AMPA receptor agonists acting at AMPA receptors expressed in Xenopus oocytes. Eur. J. Pharmacol. (1996) 308:211-218.
78. SUN G, URETSKY NJ, WALLACE LJ et al.: Synthesis of chiral 1-(2′-amino-2′-carboxyethyl -1,4-dihydro-6,7-quinoxaline-2,3-diones: α-amino-3-hydroxy-5-methyl-4-isoxazolepropionate receptor agonists and antagonists. J. Med. Chem. (1996) 39:4430-4438.
79. KRISTENSEN BW, NORABERG J, ZIMMER J: Comparison of excitotoxic profiles of ATPA, AMPA, KA and NMDA in organotypic hippocampal slice cultures. Brain Res. (2001) 917:21-44.
80. WAHL P, FRANDSEN A, MADSEN U, SCHOUSBOE A, KROGSGAARD-LARSEN P: Pharmacology and toxicology of ATOA, an AMPA receptor antagonist and a partial agonist at GluR5 receptors. Neuropharmacology (1998) 37:1205-1210.
81. JOHANSEN TN, JANIN YL, NIELSEN B et al.: 2-Amino-3-(3-hydroxy-1,2,5-thiadiazol-4-yl)propionic acid: resolution, absolute stereochemistry and enantiopharmacology at glutamate receptors. Bioorg. Med. Chem. (2002) 10:2259-2266.
82. SHEARDOWN MJ, NIELSEN EO, HANSEN AJ, JACOBSEN P, HONORE T: 2,3-Dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline: a neuroprotectant for cerebral ischemia. Science (1990) 247:571-574.
83. LUBISCH W, BEHL B, HENN C et al.: Pyrrolylquinoxalinediones carrying a piperazine residue represent highly potent and selective ligands to the homomeric kainate receptor GluR5. Bioorg. Med. Chem. Lett. (2002) 12:2113-2116.
84. MORE JC, TROOP HM, DOLMAN NP, JANE DE: Structural requirements for novel willardiine derivatives acting as AMPA and kainate receptor antagonists. Br. J. Pharmacol. (2003) 138:1093-1100.
85. MORE JC, TROOP HM, JANE DE: The novel antagonist 3-CBW discriminates between kainate receptors expressed on neonatal rat motoneurones and those on dorsal root C-fibres. Br. J. Pharmacol. (2002) 137:1125-1133.
86. BLEAKMAN D: Kainate receptor pharmacology and physiology. Cell. Mol. Life Sci. (1999) 56:558-566.
87. WITKIN J, KAMINSKI R, ROGAWSKI M: Pharmacology of Glutamate Receptors. In: Glutamate and Addiction. Herman BH (Ed.) Human Press, Totowa, USA (2003):23-50.
88. O'NEILL MJ, BOGAERT L, HICKS CA et al.: LY-377770, a novel iGlu5 kainate receptor antagonist with neuroprotective effects in global and focal cerebral ischaemia. Neuropharmacology (2000) 39:1575-1588.
89. O'NEILL MJ, BOND A, ORNSTEIN PL et al.: Decahydroisoquinolines: novel competitive AMPA/kainate antagonists with neuroprotective effects in global cerebral ischaemia. Neuropharmacology (1998) 37:1211-1222.
90. SAVIDGE JR, BLEAKMAN D, BRISTOW DR: Identification of kainate receptor-mediated intracellular calcium increases in cultured rat cerebellar granule cells. J. Neurochem. (1997) 69:1763-1766.
91. BLEAKMAN D, BALLYK BA, SCHOEPP DD et al.: Activity of 2,3-benzodiazepines at native rat and recombinant human glutamate receptors in vitro: stereospecificity and selectivity profiles. Neuropharmacology (1996) 35:1689-1702.
92. PATERNAIN AV, VICENTE A, NIELSEN EO, LERMA J: Comparative antagonism of kainate-activated kainate and AMPA receptors in hippocampal neurons. Eur. J. Neurosci. (1996) 8:2129-2136.
93. WILDING TJ, HUETTNER JE: Antagonist pharmacology of kainate- and alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid-preferring receptors. Mol. Pharmacol. (1996) 49:540-546.
94. BORTOLOTTO ZA, CLARKE VR, DELANY CM et al.: Kainate receptors are involved in synaptic plasticity. Nature (1999) 402:297-301.
95. SANG CN, HOSTETTER MP, GRACELY RH et al.: AMPA/kainate antagonist LY-293558 reduces capsaicin-evoked hyperalgesia but not pain in normal skin in humans. Anesthesiology (1998) 89:1060-1067.
96. BECKER JW, CUNNINGHAM BA, REEKE GN, WANG JL, EDELMAN GM: The molecular structure of concanavalin A. In: Concanavalin A as a tool. Schnebli HP (Ed.) John Wiley & Sons, New York (1976):33-56.
97. EVERTS I, VILLMANN C, HOLLMANN M: N-Glycosylation is not a prerequisite for glutamate receptor function but Is essential for lectin modulation. Mol. Pharmacol. (1997) 52:861-873.
98. ZORUMSKI CF, THIO LL: Properties of vertebrate glutamate receptors: calcium mobilization and desensitization. Prog. Neurobiol. (1992) 39:295-336.
99. EVERTS I, PETROSKI R, KIZELSZTEIN P et al.: Lectin-induced inhibition of desensitization of the kainate receptor GluR6 depends on the activation state and can be mediated by a single native or ectopic N-linked carbohydrate side chain. J. Neurosci. (1999) 19:916-927.
100. PATERNAIN AV, RODRIGUEZ-MORENO A, VILLARROEL A, LERMA J: Activation and desensitization properties of native and recombinant kainate receptors. Neuropharmacology (1998) 37:1249-1259.
101. KATO G, WEITSCH AF: Neurochemical profile of tianeptine, a new antidepressant drug. Clin. Neuropharmacol. (1988) 11(Suppl.2):S43-50.
102. MOCAER E, RETTORI MC, KAMOUN A: Pharmacological antidepressive effects and tianeptine-induced 5-HT uptake increase. Clin. Neuropharmacol. (1988) 11(Suppl.2):S32-42.
103. KIM YJ, SHIN MC, KIM SA et al.: Modulation of tianeptine on ion currents induced by inhibitory neurotransmitters in acutely dissociated dorsal raphe neurons of Sprague-Dawley rats. Eur. Neuropsychopharmacol. (2002) 12:417-425.
104. FILLA SA, WINTER MA, JOHNSON KW et al.: Ethyl (3S,4aR,6S,8aR)-6-(4-ethoxycarbonylimidazol-1-ylmethyl) decahydroisoquinoline-3-carboxylic ester: a prodrug of a GluR5 kainate receptor antagonist active in two animal models of acute migraine. J. Med. Chem. (2002) 45:4383-4386.
105. HORN IR, MOESTRUP SK, VAN DEN BERG BM et al.: Analysis of the binding of pro-urokinase and urokinase-plasminogen activator inhibitor-1 complex to the low density lipoprotein receptor-related protein using a Fab fragment selected from a phage-displayed Fab library. J. Biol. Chem. (1995) 270:11770-11775.
106. 3H]-kainic acid receptor binding by divalent cations correlates with ion affinity for the calcium channel. Neuropharmacology (1987) 26:1247-1251.
107. 3H]-3-(2-carboxypiperazin-4-yl propyl-1-phosphonic acid to rat brain membranes: a selective, high-affinity ligand for N-methyl-D-aspartate receptors. J. Pharmacol. Exp. Ther. (1987) 240:778-784.
108. HAMILL OP, MARTY A, NEHER E, SAKMANN B, SIGWORTH FJ: Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches. Pflugers Arch. (1981) 391:85-100.
109. GRINVALD A, HILDESHEIM R, FARBER IC, ANGLISTER L: Improved fluorescent probes for the measurement of rapid changes in membrane potential. Biophys. J. (1982) 39:301-308.
110. GRINVALD A, SALZBERG BM, LEV-RAM V, HILDESHEIM R: Optical recording of synaptic potentials from processes of single neurons using intracellular potentiometric dyes. Biophys. J. (1987) 51:643-651.
111. KARPEN JW, SACHS AB, PASQUALE EB, HESS GP: Spectrophotometric detection of monovalent cation flux in cells: fluorescence microscope measurement of acetylcholine receptor-mediated ion flux in PC-12 cells. Anal. Biochem. (1986) 157:353-359.
112. SIMMONS RM, LI DL, HOO KH et al.: Kainate GluR5 receptor subtype mediates the nociceptive response to formalin in the rat. Neuropharmacology (1998) 37:25-36.
113. IKONOMIDOU C, BOSCH F, MIKSA M et al.: Blockade of NMDA receptors and apoptotic neurodegeneration in the developing brain. Science (1999) 283:70-74.
114. KOMURO H, RAKIC P: Modulation of neuronal migration by NMDA receptors. Science (1993) 260:95-97.
115. RZESKI W, IKONOMIDOU C, TURSKI L: Glutamate antagonists limit tumor growth. Biochem. Pharmacol. (2002) 64:1195-1200.